thirdly, 8-anilino-naphtalene-sulphonic (ANS) acid does not inhibit thyroid hormone binding to both IgG and lipoproteins-; fourthly, even in animals, false positive results for T3-Ab were observed in lipemic sera'', Accordingly, plasma lipoprotein levels should be given. Anyway, specific radioimmunoprecipitation with anti-human-IgG serum is the reliable method.
(2) Table 3 : Analysis of this table makes even less convincing the presence of T4-Ab in patient A. At variance with the literature", in fact, are the supranormal levels of FT4 and normal levels of TI'4 in a euthyroid subject. The methods employed (the unaffected, by THAb, equilibrium dialysis for FT4 and the affected double-antibody RIA for TI'4) would have produced normal FT4 and, as occurred in patient B, supranormal TI4. The possibility, however, exists that the high FT4 was produced by the circulating inhibitors of the thyroid hormone binding to serum proteins frequently observed in non-thyroid illnessess.
(3) Prevalence: Taking into account the case ofT3·Ab mentioned in the discussion in the paper by Farror et al., the prevalence of THAb in the general population is 0.0003% (3/1000000). If we exclude the small series (n=182) by Merlin et al. 6 , in the other 3 available studies? the prevalence is 167 to 666 times greater. The difference is even more impressive, because the authors! used a method overestimating the frequency of detection of THAb.
(4) Specificity: Although cross-reactivity was not tested, we can deduce that two patients (2/3,75%) had THAb to T4 only and one (25%) to T3 only. Instead, THAb frequently cross-react (T3+T4±tT3) and, anyway, T3Ab are by far more frequent than T4-Ab 4 • Finally, in view of the readership of the Journal, we would like to stress that THAb are, in all probability, Ab to thyroglobulin cross-reacting with thyroid hormones and that they per se do not call for any treatment", S BENVENGA The authors reply below * Sir, We thank Dr Benvenga for his letter and for the further information he provides to your readers, including ourselves, on the methods of testing for thyroid antibodies. We agree that radioimmune precipitation with the specific anti-human-sera-IgG is theoretically a more specific method for detecting the autoantibodies than the method we used based on non-specific binding of labelled T4 or T3 in barbitone in the presence of excess blocker followed by polyethylene glycol separation. Nevertheless, the method we chose is practical, sensitive and suitable for our type of diagnostic laboratory as a screen for false positives caused by T4 or T3 antibodies. We agree that the yearly incidence of such autoantibodies are likely to be much higher than Dr Benvenga has deduced from our figures and this point is made in the last paragraph of our paper. The specimens from other patients (including the four with FDH) were referred from other hospitals in Adelaide.
Certainly, we agree that patients or individuals with this type of anomaly and with FDH must not be treated for thyroid dysfunction, this being the purpose of our paper, and our last two sentences state this clearly. Rippere has drawn attention to the possible underreporting of adverse reactions to pharmaceutical excipients. An example is given of a patient who made a recovery after having been transferred from an, orange and white anticonvulsant to an equivalent generic product.
Although the anticonvulsant concerned was not named, it seems likely that it was Epanutin. I would firstly like to make it clear that Epanutin no longer contains tartrazine which has been replaced by another dye. Secondly, may I emphasize that phenytoin, the active principal within Epanutin capsules, has a complex pharmacokinetic profile and a long history ofbioavailability differences from one product to another. We therefore recommend that patients are maintained on the same brand of phenytoin whenever this is possible and that phenytoin serum levels are checked when it is found necessary to transfer patients from one brand to another. R J S BALL
Medical Information Manager Parke-Davis Research Laboratories. Southampton
Negation of responsibility: a heavy price to pay? Sir, In his letter (April 1988 JRSM, p 242) Levy believes the time will come when every doctor will have to demonstrate his continuing ability to provide top class care and to question who is going to supervise?
Reassessment is too serious a matter to leave entirely to the inhabitants of academia: the world outside has different priorities and it is to be fervently hoped that an examining committee will receive a large component of input from patients and colleagues, senior and junior, both medical, nursing and lay. An academic examination alone would be as useful as a new house surgeon. Rather than the 'State of the art' treatment, as Levy-says, 'some outmoded concept now only partly valid' -but administered with experience, care and consideration -is more appreciated by patients than the latest technology unfeelingly applied. Some of us who don't attend many meetings because we give clinical commitments absolute priority have been responsible for innovations which, at the time, would have earned us demerits with the professors. I was using oral premedication 30 years ago, longbefore it became generally acceptable, and my records of that time show I routinely used a method of capnography during artificial ventilation. We, who regularly, reliably and without fuss attend the great majority of patients are inevitably the very people absent from high level discussion about the future of health care.
While I would have something to fear from 'peer review' I should not be unwelcoming to those who have a legitimate interest in my ability to perform safely, pleasantly and punctually. A GARDINER
Consultant Anaesthetist South East Kent Health District
Haematuria analysed Sir, Gillett and O'Reilly (September 1987 JRSM, p 559) have emphasized the importance of the earliest possible reporting by the patient to the doctor of any sign of haernaturia, since the presence of blood in the urine is an early symptom of a large proportion of serious and frequently life threatening conditions. Similarly, changes in faecal nature, colour, presence or absence of occult blood and so on, provide valuable clinical information in relation to the presence or absence of a variety of conditions which may be dangerous to health.
It is, therefore, very unfortunate that at least one large-selling domestic preparation devoted to the vague and not very convincing object of improved WC bowl hygiene should colour the water from the WC cistern a deep blue, so precluding to a very large extent the observation of normality or abnormality of urine or faeces. Preparations which leave a foam permanently on the surface of the water in the bowl are equally unhelpful. That potentially life-saving observation thus precluded in the interest of sustaining a very nebulous 'hygiene' advertising claim would seem to be carrying things much too far. R GORDON BOOTH
St Albans. Herts
Reversible pulmonary disease and eosinophilia associated with sulphasalazine Sir, Jordan and Cowan (April 1988 JRSM, P 233) noted resolution of their patient's pulmonary infiltrate after stopping sulphasalazine and felt the association precluded subsequent use of this drug. However, in their patient the long time interval between starting sulphasalazine and the development of pulmonary complications makes a causative link unlikely. We have a similar patient whose pulmonary changes and eosinophilia resolved spontaneously despite continuing sulphasalazine.
Our patient developed ulcerative colitis in 1982 when aged 19. She was treated intermittently with sulphasalazine until 1985 and continuously thereafter. In July '1987, when taking sulphasalazine 4 g daily and prednisolone 7.5 mg daily, she presented with a 2 week history of shortness of breath, weight loss and cough. Chest X-ray showed extensive bilateral pulmonary infiltrates. White blood cell count was 8300 of which 12% were eosinophils. Investigations including proximal and distal bronchial biopsy, washings and smear, legionella, mycoplasma and psittacosis titres showed no abnormality. SuIphasalazine was considered as a possible cause but thought unlikely because of the long time interval before presentation. The patient was continued on the same dose of both sulphasalazine and prednisolone. On no other specific treatment her symptoms settled over 3 weeks and the X-ray changes resolved over the next 3 months. By October 1987, while still on sulphasalazine 4 g daily, her chest X-ray was normal and eosinophil count 1% of 5400. Her prednisolone had been reduced to 5 mg daily and was subsequently tailed off. Six months later her chest X-ray remained clear.
This case illustrates that primary pulmonary eosinophilia may often be a self limiting condition and should not be assumed to be drug related especially when there is a long time interval between commencement of the drug and development of symptoms. P N TREWBY Memorial Hospital. Darlington C K CONNOLLY Numerical methods for decision-making in clinical c;are: where to now? Sir, Was it fortuitous that Dr Young's editorial on the above subject was printed in the same issue as the interesting paper by Wood and Keen on 'Say yes to life: a pilot study' (March 1988 JRSM, p 128 and p 152)?
Could it be that the reason why computers have not taken over clinical decision-making is that the majority of doctors say YES to life? A E HUGH North Staffordshire Royal Infirmary Stoke-on-Trent
